Drug Profile
Research programme: epigenetic therapeutics - GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; SuperGen
- Developer GSK
- Class
- Mechanism of Action Genetic process modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer